December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 16, 2024

Smoke Travels 2,100 Miles, Hits Heart Health

A case-only study published in JAMA Network Open reveals a significant increase in cardiopulmonary clinical encounters in Maryland during June 2023, associated with remote wildfire smoke exposure, extending beyond the immediate wildfire vicinity.

Conexiant

December 13, 2024

New Vaccine Prevents Severe RSV Illness

A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

Conexiant

December 11, 2024

Do E-Cigarettes Aid Long-Term Smoking Cessation?

A recent study found that e-cigarette use was associated with lower long-term smoking cessation rates compared to traditional methods like nicotine replacement therapy.

Conexiant

December 11, 2024

Vitamin D Tied to ICU Survival

A study on ICU patients with sepsis-associated acute kidney injury revealed a 41% lower risk of in-hospital mortality with vitamin D supplementation, highlighting the potential benefits of this approach. Source: Frontiers in Medicine

Conexiant

December 09, 2024

Do SGLT2i, GLP-1 RAs Cut Pneumonia, Sepsis Risk?

In the largest real-world study to date, GLP-1 receptor agonists reduced pneumonia risk by 40% in type 2 diabetes patients.

Conexiant

December 06, 2024

COPD Treatment Patterns and Exacerbations: A 4-Year Study

A recent study in the United States revealed low adherence to guideline-directed therapy and underutilization of recommended maintenance therapies among patients newly diagnosed with chronic obstructive pulmonary disease.

Conexiant

December 06, 2024

Can Fostamatinib Improve Hypoxemia in COVID-19?

A recent study evaluated the effectiveness of fostamatinib in hospitalized adults with COVID-19 infections and hypoxemia, finding no significant improvement in oxygen-free days or reduction in mortality.

Conexiant

December 03, 2024

Roivant Ends Lung Drug After Trial

Roivant discontinues injectable drug namilumab for treating chronic active pulmonary sarcoidosis, citing failure to show treatment benefits in mid-stage trial.

Reuters